THE MAIN REASONS WHY CANCER IS SO DIFFICULT TO TREATMENT
ALI ADEL DAWOOD *
College of Medicine, University of Mosul, Mosul, Iraq.
WALEED ISMAEEL YOUSIF
College of Medicine, University of Nineveh, Mosul, Iraq.
*Author to whom correspondence should be addressed.
Abstract
The “Type of Article” of this paper is “Letter to the Editor”. This paper discuses about: “THE MAIN REASONS WHY CANCER IS SO DIFFICULT TO TREATMENT”. No formal abstract is available. Readers are requested to read the full article.
How to Cite
Downloads
References
Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–837.
Copland M, Jorgensen HG, Holyoake TL. Evolving molecular therapy for chronic myeloid leukaemia-are we on target? Hematology. 2005;10:349–359.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol; 2013 [PubMed].
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–1570.
Abrams J, Conley B, Mooney M. National cancer institute's precision medicine initiatives for the new national clinical trials network. Am. Soc. Clin. Oncol. Educ. Book. 2014;71–76. [PubMed].
Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat. Rev. Cancer. 2014;14:623–631.
Galluzzi L, Vacchelli E, Bravo-San Pedro J-M, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–12508.
Catenacci DVT. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967–996.
FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab), Merk; 2020. Available:https://www.merck.com/?s=Keytruda.
Bang YJ, Van Cutsem E. Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.